Genzyme Corp."s decision to discard 80 percent of the material it had on hand to produce the enzyme disorder drug, Cerezyme [imiglucerase], will cause longer delays in production but the company has issued guidelines which will preserve full doses for patients under 18 and those suffering from the most severe versions of Gaucher disease. According to the company the Boston facility which was closed due to a contaminating virus has resumed operating with all bioreactors expected to be operational in August. New lots of the drug will be shipped in November and December.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지